Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 double-blind placebo-controlled study of AFT-801 (modafinil) for excessive daytime sleepiness in CPAP-treated obstructive sleep apnea
jRCT2080220749Phase 3
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Jun 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Excessive Daytime Sleepiness (EDS) and obstructive sleep apnea hypopnea syndrome (OSAHS) comparing AFT-801 (modafinil) with Placebo (2 arms).
02
Drugs
modafinil
03
Conditions
Excessive Daytime Sleepiness (EDS)obstructive sleep apnea hypopnea syndrome (OSAHS)
Beyond the preview
Go deeper on jRCT2080220749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220749.